[Research Progress of Angiogenesis Inhibitors Plus EGFR-TKI in EGFR-mutated 
Advanced Non-small Cell Lung Cancer].

Lung cancer is one of the leading causes of cancer-related morbidity and mortality. Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) have become the standard treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). Unfortunately, drug resistance is inevitable in most cases. EGFR-TKI combined with angiogenesis inhibitors is a treatment scheme being explored to delay the therapeutic resistance, which is called "A+T treatment". Several clinical trials have demonstrated that the A+T treatment can improve the progression free survival (PFS) of the NSCLC patients. However, compared to EGFR-TKI monotherapy, the benefits of the A+T treatment based on different EGFR-TKIs, as well as its safety and exploration prospects are still unclear. Therefore, we reviewed the literature related to all three generations EGFR-TKIs combined with angiogenesis inhibitors, and summarized the mechanism, benefit, safety, optimal target population of A+T treatment. .【中文题目：抗血管生成药物联合EGFR-TKI治疗EGFR突变晚期非小细胞肺癌的研究进展】 【中文摘要：肺癌是最常见、致死率最高的肿瘤性疾病之一，使用表皮生长因子受体酪氨酸激酶抑制剂（epidermal growth factor receptor tyrosine kinase inhibitor, EGRF-TKI）已经成为EGFR突变晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的标准治疗方式。然而耐药事件的发生往往是不可避免的。EGFR-TKI联合抗血管生成药物（angiogenesis inhibitor）是目前一种正在探索的延缓耐药事件发生的治疗方案，被称为“A+T治疗”。多项临床试验已经证明A+T治疗相较于单药可以延长患者的无进展生存期（progression free survival, PFS）。然而，基于不同EGFR-TKI的A+T治疗相对于EGFR-TKI单药治疗所带来的获益程度、安全性和探索前景仍不明确。因此，我们回顾了第一、二、三代EGFR-TKI联合抗血管生成药物治疗的相关文献，总结了A+T治疗模式的增益机制、获益程度、安全性以及最佳的目标人群。 】 【中文关键词：肺肿瘤；表皮生长因子受体；抗血管生成药物；联合治疗】.